Molly Harper

Biography

Molly Harper has more than 2 decades of leading biopharma businesses in growth across settings ranging from large biopharmaceutical companies to entrepreneurial start-ups, with a particular focus on therapeutics for rare diseases. Ms. Harper is currently Managing Partner for Peacock Hall LLC., an advisory firm focused on life sciences companies. She previously served as Chief Business Officer for Synlogic, Inc., a clinical-stage biotechnology company pioneering therapeutics based on synthetic biology, where her responsibilities spanned business development, investor relations and corporate communications, new product planning, commercial strategy, and patient advocacy. Ms. Harper joined Synlogic from Relmada Therapeutics, Inc., where she was Executive Vice President of Operations. Prior to Relmada, she served in positions of increasing responsibility with Akcea Therapeutics, most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the global commercialization of two rare disease drugs, having designed and built a scalable, global commercial organization. Ms. Harper previously served as Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, and in commercial leadership roles with Merck & Co. She began her career in equity research at UBS Warburg and strategy consulting at The Wilkerson Group/IBM.

Ms. Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from The Wharton School of the University of Pennsylvania. Ms. Harper also serves on the Board of Directors of PreciseDx, a privately held AI oncology pathology company.